Key Points
- Michael Alexander Smith sold 19,638 shares of Insmed on March 30 at an average price of $150.98 for roughly $2.96M, reducing his ownership by 27.46% to 51,871 shares (disclosed in an SEC Form 4).
- Mixed fundamentals but bullish analyst sentiment: Insmed missed quarterly EPS estimates (‑$1.54 vs. ‑$1.07) while revenue roughly met expectations and rose 152.6% year‑over‑year, yet the stock carries an average "Buy" rating with a $212.67 target after multiple recent upgrades and price‑target increases.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Michael Alexander Smith sold 19,638 shares of the company's stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the sale, the insider directly owned 51,871 shares in the company, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Michael Alexander Smith also recently made the following trade(s):
- On Tuesday, February 3rd, Michael Alexander Smith sold 640 shares of Insmed stock. The stock was sold at an average price of $156.27, for a total value of $100,012.80.
- On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $183,401.01.
- On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $124,124.63.
- On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $241,968.68.
Insmed Stock Down 1.5%
Shares of Insmed stock opened at $162.43 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The firm has a market cap of $35.01 billion, a price-to-earnings ratio of -25.34 and a beta of 1.10. The company has a 50-day moving average of $150.18 and a 200 day moving average of $166.38. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million during the quarter, compared to analysts' expectations of $263.97 million. During the same quarter last year, the company posted ($1.32) EPS. Insmed's revenue for the quarter was up 152.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Insmed
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company's stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. lifted its holdings in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company's stock valued at $3,644,274,000 after purchasing an additional 475,832 shares in the last quarter. Capital International Investors boosted its position in shares of Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company's stock valued at $1,087,830,000 after buying an additional 74,994 shares during the last quarter. State Street Corp boosted its position in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company's stock valued at $905,312,000 after buying an additional 1,217,390 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock worth $711,076,000 after buying an additional 1,623,342 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on INSM. Stifel Nicolaus raised their price objective on Insmed from $205.00 to $208.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Jefferies Financial Group assumed coverage on Insmed in a report on Monday, March 16th. They issued a "buy" rating and a $228.00 target price on the stock. The Goldman Sachs Group increased their target price on Insmed from $225.00 to $258.00 and gave the stock a "buy" rating in a research note on Monday, December 15th. Leerink Partners lifted their price target on Insmed from $210.00 to $215.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 24th. Finally, Wells Fargo & Company dropped their price target on shares of Insmed from $208.00 to $175.00 and set an "overweight" rating on the stock in a research note on Monday, March 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $212.67.
Check Out Our Latest Stock Analysis on Insmed
Key Insmed News
Here are the key news stories impacting Insmed this week:
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
